about
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analoguesPharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin AN-acetyl-S-(N,N-diethylcarbamoyl) cysteine in rat nucleus accumbens, medial prefrontal cortex, and in rat and human plasma after disulfiram administrationRole of Ventral Subiculum in Context-Induced Relapse to Alcohol Seeking after Punishment-Imposed AbstinenceDevelopment of functionally selective, small molecule agonists at kappa opioid receptors.Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitroBehavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in RatsTime course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.Holo Structure and Steady State Kinetics of the Thiazolinyl Imine Reductases for Siderophore Biosynthesis.Synthesis and Opioid Activity of Tyr1 -ψ[(Z)CF=CH]-Gly2 and Tyr1 -ψ[(S)/(R)-CF3 CH-NH]-Gly2 Leu-enkephalin Fluorinated Peptidomimetics.Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.Correction to "Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over βArrestin2 Signaling Bias".Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens.The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.Scalable Regioselective and Stereoselective Synthesis of Functionalized (E)-4-Iodobut-3-en-1-ols: Gram-Scale Total Synthesis of Fungal Decanolides and Derivatives.Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in miceKappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in RodentsKappa opioid agonists reduce oxycodone self-administration in male rhesus monkeysStuffed Methyltransferase Catalyzes the Penultimate Step of Pyochelin BiosynthesisFurther exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolinesImpact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male MicePreclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist MorphineDiscovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay
P50
Q34547230-152D549F-16FA-44CD-85B8-B32A085F7180Q34796464-4F647DEC-B267-4ECA-93E8-C047498CB1FCQ34939810-9A46370A-E192-43F8-84E0-102EB7C75417Q35538963-C81FD06F-4CE6-46CE-863D-7F111DA56660Q36690137-9665829A-4918-4662-8651-4682D91CD7D9Q37405071-ECB65FE1-575E-4AF7-834A-127EE4FF8919Q37419558-8A602621-01FF-4ABC-A8D3-FF7BEEEB19A6Q37458190-85BA2AFC-17C5-4FDC-AAC3-B8EF2C72CB6FQ37621277-81227C43-A776-4B3A-80B3-40D4AF3027A7Q39416679-535C29AD-9ABB-417F-ABE6-D9DD0D74BA86Q44343990-80F15198-47C6-4887-A9FE-8B5586132DA0Q44344643-841CFBCF-3A69-4E13-832E-AF711D633A1DQ44345909-FDB16CA8-C37A-47AE-B4C9-3DA77D5788B9Q44347299-02B68808-F398-42BA-A9EF-B1E1860CFCDCQ47682915-45B0A186-3F7E-4191-93A5-2547E48CD664Q47977698-33332A95-B7CF-423B-8517-24B01191372CQ48358898-F3AF5FCE-353F-4584-BF4A-74E65F54E197Q50591898-873EA078-9F0A-4667-B030-948752C89AF1Q57299911-C00B5FFE-E2C7-4348-93C2-3A6537CFDA29Q57476500-0FC42D96-D3B9-4D69-8C80-7FE55614A06DQ89475838-A2CC8CB5-62E2-4D28-BFDA-A8A2B1058A4DQ90330715-4FC11A8D-CF68-4621-B03A-E96BBA7655E2Q91556853-4C4FB5D8-869A-4F2A-BF16-B4AFF7F3EC2DQ93039689-A12546B1-C265-4145-88C5-26751B902811Q93161734-9E48DF02-96D2-493E-9E64-EAAA3AA05853Q93162031-B15B4B4D-977A-45A3-BA09-4159638C45DC
P50
description
researcher
@en
name
Thomas E Prisinzano
@en
type
label
Thomas E Prisinzano
@en
prefLabel
Thomas E Prisinzano
@en
P31
P496
0000-0002-0649-8052